Innovative Small-Cap Biopharma Companies Lead the Future of Pain Therapy
The transdermal patch market, especially for pain therapy, is experiencing significant growth, offering safer alternatives to traditional opioid use and attracting investor interest in small-cap biopharma companies.
The global transdermal patch market, valued at $7.8 billion in 2023, is projected to reach nearly $10.95 billion by 2030, with pain patches leading the growth from $4.8 billion in 2021 to $7.3 billion by 2031. This growth is not just about convenience but also addresses critical healthcare challenges, such as managing chronic pain in aging populations and providing needle-free medication delivery, offering a safer alternative to traditional opioid use.
Nutriband Inc. (NASDAQ: NTRB) is emerging as a disruptive force in opioid pain management with its AVERSA Fentanyl patch, designed to deter abuse through its proprietary AVERSA technology. The company, generating revenue through its Pocono Pharma subsidiary, is progressing towards filing an Investigational New Drug application with the FDA, supported by a broad international IP portfolio.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) is making strides in the pain and neuropsychiatry treatment markets, with its ADHD medication Jornay PM and chronic pain medications showing significant revenue growth. The company's strong financial performance supports its aggressive capital deployment strategy, including a $25 million accelerated share repurchase.
Assertio Holdings, Inc. (Nasdaq: ASRT) is transitioning into a specialty pharmaceutical company, focusing on high-potential assets and business development after settling multiple lawsuits and divesting legacy obligations. Its products Rolvedon and Sympazan are outperforming expectations, setting the stage for revenue expansion.
Aquestive Therapeutics, Inc. (Nasdaq: AQST) is advancing innovative, non-invasive treatments for severe allergic reactions, with its Anaphylm™ oral sublingual film nearing FDA approval. Despite a net loss in Q1 2025, the company is preparing for a potential U.S. launch in early 2026, aiming to offer a new option for patients with severe allergic reactions.
These companies represent the forefront of innovation in pain therapy and drug delivery, addressing significant healthcare needs while offering investors opportunities in the growing transdermal patch market.